ulipristal acetate has been researched along with asoprisnil in 9 studies
| Studies (ulipristal acetate) | Trials (ulipristal acetate) | Recent Studies (post-2010) (ulipristal acetate) | Studies (asoprisnil) | Trials (asoprisnil) | Recent Studies (post-2010) (asoprisnil) |
|---|---|---|---|---|---|
| 376 | 41 | 347 | 48 | 8 | 17 |
| Protein | Taxonomy | ulipristal acetate (IC50) | asoprisnil (IC50) |
|---|---|---|---|
| Estrogen receptor | Homo sapiens (human) | 1.95 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.1025 | |
| Progesterone receptor | Homo sapiens (human) | 0.0003 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 1.6 | |
| Androgen receptor | Homo sapiens (human) | 0.0075 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Weys, D; Enthoven, M; Golstein, I; Hamersma, H; Rewinkel, J; Scholten, A; van der Rijst, M; van Tilborg, M; Wisse, J | 1 |
| Sarkar, NN | 1 |
| Manyonda, I; Talaulikar, VS | 1 |
| Bastianelli, C; Benagiano, G; Brosens, I; Farris, M | 1 |
| Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
| Centini, G; Kashani, BN; Morelli, SS; Petraglia, F; Weiss, G | 1 |
| Chow, TL; Murji, A; Sobel, ML; Whitaker, L | 1 |
| Belland, L; Leyland, N; Murji, A; Singh, SS; von Riedemann, S | 1 |
| Acosta, K; Binkley, P; Dileep, KV; Nair, HB; Nickisch, K; Santhamma, B; Schenken, R; Zhang, KYJ | 1 |
6 review(s) available for ulipristal acetate and asoprisnil
| Article | Year |
|---|---|
Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids.
Topics: Endometrium; Estrenes; Female; Hormone Antagonists; Humans; Hyperplasia; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone | 2012 |
Selective progesterone receptor modulators: an update.
Topics: Adenomyosis; Animals; Clinical Trials as Topic; Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Endometriosis; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone; Uterine Neoplasms | 2014 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
Role of Medical Management for Uterine Leiomyomas.
Topics: Antifibrinolytic Agents; Aromatase Inhibitors; Cabergoline; Cholecalciferol; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Contraceptives, Oral, Synthetic; Danazol; Dopamine Agonists; Ergolines; Estrenes; Estrogen Antagonists; Female; Gestrinone; Gonadotropin-Releasing Hormone; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Patient Care Planning; Selective Estrogen Receptor Modulators; Somatostatin; Tranexamic Acid; Uterine Neoplasms; Vitamins | 2016 |
Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Topics: Amenorrhea; Antineoplastic Agents, Hormonal; Estrenes; Female; Humans; Leiomyoma; Leuprolide; Menstruation; Mifepristone; Norpregnadienes; Oximes; Pelvic Pain; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Uterine Neoplasms | 2017 |
The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Topics: Contraceptive Agents, Female; Disease Management; Estrenes; Female; Forecasting; Humans; Leiomyoma; Mifepristone; Norpregnadienes; Oximes; Population Growth; Receptors, Progesterone; Steroids; Uterine Neoplasms | 2018 |
3 other study(ies) available for ulipristal acetate and asoprisnil
| Article | Year |
|---|---|
11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists.
Topics: Ligands; Pregnanes; Progesterone; Receptors, Progesterone; Steroids; Structure-Activity Relationship | 2008 |
The state-of-the-art of emergency contraception with the cutting edge drug.
Topics: Contraception, Postcoital; Contraceptive Agents, Female; Estrenes; Female; Gonanes; Humans; Mifepristone; Norpregnadienes; Oximes; Pregnancy; Receptors, Progesterone | 2011 |
EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Topics: Animals; Cell Proliferation; Contraceptive Agents, Female; Estrenes; Female; Humans; Leiomyoma; Mice; Molecular Docking Simulation; Molecular Structure; Norpregnadienes; Oximes; Progesterone Congeners; Receptors, Progesterone; Structure-Activity Relationship; Uterine Neoplasms; Uterus; Xenograft Model Antitumor Assays | 2019 |